Your browser doesn't support javascript.
loading
From Uterus to Brain: An Update on Epidemiology, Clinical Features, and Treatment of Brain Metastases From Gestational Trophoblastic Neoplasia.
Borella, Fulvio; Cosma, Stefano; Ferraioli, Domenico; Preti, Mario; Gallio, Niccolò; Valabrega, Giorgio; Scotto, Giulia; Rolfo, Alessandro; Castellano, Isabella; Cassoni, Paola; Bertero, Luca; Benedetto, Chiara.
Afiliação
  • Borella F; Division of Gynecology and Obstetrics 1, "City of Health and Science University Hospital", University of Turin, Turin, Italy.
  • Cosma S; Department of Surgical Sciences, University of Turin, Turin, Italy.
  • Ferraioli D; Division of Gynecology and Obstetrics 1, "City of Health and Science University Hospital", University of Turin, Turin, Italy.
  • Preti M; Department of Surgical Sciences, University of Turin, Turin, Italy.
  • Gallio N; Department of Oncology Surgery, Centre Léon Berard (CLB), Lyon, France.
  • Valabrega G; Division of Gynecology and Obstetrics 1, "City of Health and Science University Hospital", University of Turin, Turin, Italy.
  • Scotto G; Department of Surgical Sciences, University of Turin, Turin, Italy.
  • Rolfo A; Division of Gynecology and Obstetrics 1, "City of Health and Science University Hospital", University of Turin, Turin, Italy.
  • Castellano I; Department of Surgical Sciences, University of Turin, Turin, Italy.
  • Cassoni P; Department of Oncology, University of Torino, Torino, Italy.
  • Bertero L; Department of Oncology, University of Torino, Torino, Italy.
  • Benedetto C; Department of Surgical Sciences, University of Turin, Turin, Italy.
Front Oncol ; 12: 859071, 2022.
Article em En | MEDLINE | ID: mdl-35493999
ABSTRACT
In this review, we provide the state of the art about brain metastases (BMs) from gestational trophoblastic neoplasia (GTN), a rare condition. Data concerning the epidemiology, clinical presentation, innovations in therapeutic modalities, and outcomes of GTN BMs are comprehensively presented with particular attention to the role of radiotherapy, neurosurgery, and the most recent chemotherapy regimens. Good response rates have been achieved thanks to multi-agent chemotherapy, but brain involvement by GTNs entails significant risks for patients' health since sudden and extensive intracranial hemorrhages are possible. Moreover, despite the evolution of treatment protocols, a small proportion of these patients ultimately develops a resistant disease. To tackle this unmet clinical need, immunotherapy has been recently proposed. The role of this novel option for this subset of patients as well as the achieved results so far are also discussed.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Screening_studies Idioma: En Revista: Front Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Screening_studies Idioma: En Revista: Front Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália
...